NTLA vs. CLDX, MYGN, QDEL, NEOG, EDIT, CRSP, CLLS, SGMO, LNTH, and JANX
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), QuidelOrtho (QDEL), Neogen (NEOG), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Cellectis (CLLS), Sangamo Therapeutics (SGMO), Lantheus (LNTH), and Janux Therapeutics (JANX). These companies are all part of the "medical" sector.
Intellia Therapeutics (NASDAQ:NTLA) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
Intellia Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Celldex Therapeutics received 181 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 69.37% of users gave Intellia Therapeutics an outperform vote.
In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Celldex Therapeutics' average media sentiment score of 1.36 beat Intellia Therapeutics' score of 1.29 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Intellia Therapeutics has a net margin of -893.34% compared to Celldex Therapeutics' net margin of -2,385.57%. Celldex Therapeutics' return on equity of -29.55% beat Intellia Therapeutics' return on equity.
88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.0% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Intellia Therapeutics currently has a consensus price target of $66.77, suggesting a potential upside of 193.88%. Celldex Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 86.55%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.
Celldex Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Celldex Therapeutics beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
